The Prolaris cell-cycle progression test could reduce overtreatment of localized prostate cancer, recent data suggest.
Prolaris is a genomic test developed to help predict prostate cancer aggressiveness, which can be used along with clinical parameters, such as Gleason score and PSA.
Researchers reported at the European Society for Medical Oncology European Cancer Congress in Vienna, Austria on a study, called EMPATHY-P, in which they used the cell-cycle progression score to assess and stratify prostate cancer aggressiveness in newly diagnosed patients from 26 sites in Europe. They classified prostate cancer aggressiveness according to clinical risk category and then reclassified it by cell-cycle progression score in each category. Finally, they assessed planned treatment patterns in each risk category in relation to the individual clinical risk category, according to the poster.
Data for each protocol analysis was available for 502 patients, with a median age of 68 years.